From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Variables | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
OR | 95% CI | p | OR | 95% CI | p | |
Gender | ||||||
Female | ref | |||||
Male | 3.13 | 1.27–7.67 | 0.013* | |||
WBC | 1.61 | 1.29–2.00 | < 0.001* | 1.58 | 1.26–2.01 | < 0.001* |
Neutrophil | 1.13 | 0.93–1.37 | 0.229 | |||
Platelet | 0.98 | 0.97–0.98 | 0.026* | |||
ELABELA | 1.31 | 1.13–1.52 | < 0.001* | 1.38 | 1.17–1.63 | < 0.001* |
Nagelkerke R2 = 0.849; p < 0.001* |